Trivedi, J. and Mahajan, D. and Jaffe, R.J. and Acharya, A. and Mitra, D. and Byrareddy, S.N. (2020) Recent Advances in the Development of Integrase Inhibitors for HIV Treatment. Current HIV/AIDS Reports. pp. 63-75.

Full text not available from this repository. (Request a copy)

Abstract

Purpose of the Review The complex multistep life cycle of HIV allows it to proliferate within the host and integrate its genome in to the host chromosomal DNA. This provirus can remain dormant for an indefinite period. The process of integration, governed by integrase (IN), is highly conserved across the Retroviridae family. Hence, targeting integration is not only expected to block HIV replication but may also reveal new therapeutic strategies to treat HIV as well as other retrovirus infections. Recent Findings HIV integrase (IN) has gained attention as the most promising therapeutic target as there are no equivalent homologues of IN that has been discovered in humans. Although current nano-formulated long-acting IN inhibitors have demonstrated the phenomenal ability to block HIV integration and replication with extraordinary half-life, they also have certain limitations.Summary In this review, we have summarized the current literature on clinically established IN inhibitors, their mechanism of action, the advantages and disadvantages associated with their therapeutic application, and finally current HIV cure strategies using these inhibitors.

Item Type:	Article
Depositing User:	Mr. Rameshwar Nema
Date Deposited:	26 Feb 2020 05:11
Last Modified:	26 Feb 2020 05:11
URI:	http://nccs.sciencecentral.in/id/eprint/793

Actions (login required)

View Item